Literature DB >> 2684519

Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.

J T Sobota1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684519

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  5 in total

Review 1.  Controversies in determination of epoetin (recombinant human erythropoietin) dosages.

Authors:  P A Abraham; W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

3.  The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure.

Authors:  S Túri; I Németh; I Varga; T Bodrogi; B Matkovics
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

4.  Iron therapy in the pediatric hemodialysis population.

Authors:  Bradley A Warady; Annamaria Kausz; Gary Lerner; Eileen D Brewer; Vimal Chadha; Carlo Brugnara; Naomi V Dahl; Sandra L Watkins
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

5.  Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Authors:  Jorge F Pérez-Oliva; Martha Casanova-González; Idrian García-García; Pedro J Porrero-Martín; Carmen M Valenzuela-Silva; Tairí Hernández-Montero; Marcia Lagarde-Ampudia; Yuri Casanova-Kutsareva; Yisel Avila-Albuerne; Alicia Vargas-Batista; Hailen Bobillo-López; Raúl Herrera-Valdés; Pedro A López-Saura
Journal:  BMC Nephrol       Date:  2005-05-23       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.